Candel Therapeutics, Inc. (CADL)
11.31
-0.86
(-7.07%)
USD |
NASDAQ |
Sep 10, 14:41
Candel Therapeutics Enterprise Value : 774.31M for Sept. 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 09, 2026 | 774.31M |
| September 08, 2026 | 807.04M |
| September 04, 2026 | 820.74M |
| September 03, 2026 | 835.21M |
| September 02, 2026 | 852.71M |
| September 01, 2026 | 826.07M |
| August 31, 2026 | 842.82M |
| August 28, 2026 | 842.82M |
| August 27, 2026 | 894.58M |
| August 26, 2026 | 858.80M |
| August 25, 2026 | 883.16M |
| August 24, 2026 | 826.83M |
| August 21, 2026 | 847.39M |
| August 20, 2026 | 788.01M |
| August 19, 2026 | 875.55M |
| August 18, 2026 | 765.18M |
| August 17, 2026 | 773.55M |
| August 14, 2026 | 740.06M |
| August 13, 2026 | 746.15M |
| August 12, 2026 | 660.90M |
| August 11, 2026 | 658.61M |
| August 10, 2026 | 647.19M |
| August 07, 2026 | 654.04M |
| August 06, 2026 | 653.28M |
| August 05, 2026 | 644.15M |
| Date | Value |
|---|---|
| August 04, 2026 | 647.96M |
| August 03, 2026 | 614.46M |
| July 31, 2026 | 609.90M |
| July 30, 2026 | 599.24M |
| July 29, 2026 | 563.46M |
| July 28, 2026 | 584.78M |
| July 27, 2026 | 606.09M |
| July 24, 2026 | 575.64M |
| July 23, 2026 | 598.48M |
| July 22, 2026 | 615.99M |
| July 21, 2026 | 625.88M |
| July 20, 2026 | 576.40M |
| July 17, 2026 | 622.84M |
| July 16, 2026 | 569.55M |
| July 15, 2026 | 581.73M |
| July 14, 2026 | 599.24M |
| July 13, 2026 | 581.73M |
| July 10, 2026 | 570.31M |
| July 09, 2026 | 600.76M |
| July 08, 2026 | 600.00M |
| July 07, 2026 | 597.72M |
| July 06, 2026 | 611.42M |
| July 02, 2026 | 596.19M |
| July 01, 2026 | 600.00M |
| June 30, 2026 | 631.97M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.882B |
| Alnylam Pharmaceuticals, Inc. | 34.18B |
| Anika Therapeutics, Inc. | 266.28M |
| Savara, Inc. | 969.61M |
| Vericel Corp. | 1.927B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -38.90M |
| Total Expenses (Quarterly) | 38.90M |
| EPS Diluted (Quarterly) | -0.5248 |
| Earnings Yield | -12.46% |
| Normalized Earnings Yield | -10.80 |